Changxing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Changxing Li has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Kang Zeng
Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China
17 shared publications Qi Wang
Department of Dermatology, Southern Hospital, Southern Medical University, Guangzhou, China
9 shared publicationsPingjiao Chen
Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China
7 shared publications- Xibao Zhang
Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China
5 shared publications Chenxi Zhang
4 shared publicationsXin Tian
Guangzhou Inst Dermatol, Guangzhou, Guangzhou Provi, Peoples R China
4 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 60, 105534
ALA-PDT induces apoptosis in HPV-transformed cells through mtDNA release-mediated activation of the cGAS-STING pathway
- 2 June 2026
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 60, 105534
Open AccessALA-PDT induces apoptosis in HPV-transformed cells through mtDNA release-mediated activation of the cGAS-STING pathway
- Open Access
- 1 January 2026
- Published by Kare Publishing in Journal of Clinical Practice and Research
- Vol. 48 (3) , 235-245
Symmetrical Acral Keratoderma and Ichthyosis Vulgaris: Related or Independent?
Objective: Symmetrical acral keratoderma (SAK) is a rare dermatosis that primarily affects young males and manifests as symmetric, brownish, well-demarcated hyperkeratotic plaques on acral sites, particularly the wrists, dorsal hands, and fingers. Ichthyosis vulgaris (IV), the most common subtype of ichthyosis, is characterized by dry, rough skin with fine, adherent, diamond-shaped or polygonal scales on the extensor surfaces of the limbs and trunk. Clinical evidence frequently links the onset of SAK with the presence of IV. However, systematic analyses of this association remain limited. Materials and Methods: We searched PubMed, Web of Science, and the China National Knowledge Infrastructure (CNKI) for English- and Chinese-language literature. Results: The comparative analysis revealed key parallels and distinctions. SAK predominantly affects young males and is exacerbated in hot and humid climates. IV typically manifests in infancy or early childhood, persists lifelong, and worsens during cold, dry winters. Both disorders involve FLG mutations at distinct loci. Clinically, SAK presents as symmetrically distributed, well-demarcated tan-to-dark brown macules or papules on acral sites, excluding the palms and soles. IV is characterized by light-to-dark brown diamond-shaped or polygonal scales with central adhesion and peripheral detachment, primarily on the extensor surfaces of the lower limbs. Histopathologically, SAK shows marked hyperkeratosis, thinning of the granular layer, and increased basal melanocytes. IV demonstrates mild-to-moderate hyperkeratosis with attenuation or absence of the granular layer and follicular keratin plugs. Both conditions are managed symptomatically with topical emollients and salicylic acid. Systemic approaches differ: retinoids are frequently used for IV but are seldom indicated for SAK. Conclusion: This systematic comparative analysis delineates the salient features of SAK and IV, suggesting that they may be classified as distinct disease entities.
- 1 January 2026
- Published by Kare Publishing in Journal of Clinical Practice and Research
- Vol. 48 (3) , 235-245
Open AccessSymmetrical Acral Keratoderma and Ichthyosis Vulgaris: Related or Independent?
Objective: Symmetrical acral keratoderma (SAK) is a rare dermatosis that primarily affects young males and manifests as symmetric, brownish, well-demarcated hyperkeratotic plaques on acral sites, particularly the wrists, dorsal hands, and fingers. Ichthyosis vulgaris (IV), the most common subtype of ichthyosis, is characterized by dry, rough skin with fine, adherent, diamond-shaped or polygonal scales on the extensor surfaces of the limbs and trunk. Clinical evidence frequently links the onset of SAK with the presence of IV. However, systematic analyses of this association remain limited. Materials and Methods: We searched PubMed, Web of Science, and the China National Knowledge Infrastructure (CNKI) for English- and Chinese-language literature. Results: The comparative analysis revealed key parallels and distinctions. SAK predominantly affects young males and is exacerbated in hot and humid climates. IV typically manifests in infancy or early childhood, persists lifelong, and worsens during cold, dry winters. Both disorders involve FLG mutations at distinct loci. Clinically, SAK presents as symmetrically distributed, well-demarcated tan-to-dark brown macules or papules on acral sites, excluding the palms and soles. IV is characterized by light-to-dark brown diamond-shaped or polygonal scales with central adhesion and peripheral detachment, primarily on the extensor surfaces of the lower limbs. Histopathologically, SAK shows marked hyperkeratosis, thinning of the granular layer, and increased basal melanocytes. IV demonstrates mild-to-moderate hyperkeratosis with attenuation or absence of the granular layer and follicular keratin plugs. Both conditions are managed symptomatically with topical emollients and salicylic acid. Systemic approaches differ: retinoids are frequently used for IV but are seldom indicated for SAK. Conclusion: This systematic comparative analysis delineates the salient features of SAK and IV, suggesting that they may be classified as distinct disease entities.
- Open Access
- 1 January 2026
- Published by Kare Publishing in Journal of Clinical Practice and Research
- Vol. 47 (6) , 565-572
1. Dupilumab-Induced Immune Drift Phenomena in Atopic Dermatitis: Novel Insights into Mechanisms and Therapeutic Strategies
Atopic dermatitis (AD) and psoriasis exhibit opposing T-cell polarization patterns and cytokine axes. Dupilumab, a monoclonal antibody targeting the interleukin-4/interleukin-13 (IL-4/IL-13) signaling pathway, has become a first-line biologic for moderate-to-severe AD. However, emerging clinical observations reveal that some patients with AD develop psoriasiform eruptions following biologic therapy, while certain patients with psoriasis may conversely develop eczematous lesions after corresponding biologic treatments. This paradoxical immune response has been termed the "immune drift phenomenon." This review synthesizes current evidence regarding the immunological mechanisms, clinical manifestations, histopathological characteristics, temporal patterns, and therapeutic strategies associated with this phenomenon, with particular emphasis on comprehensive management approaches, including topical therapies, systemic medication adjustments, biologic switching, and targeted small-molecule agents. In particular, it is important to acknowledge the potential limitations of small-molecule inhibitors, such as Janus kinase (JAK) inhibitors, or combination biologic therapies for managing immune drift, including the current lack of robust long-term safety and efficacy data in this specific context. We aim to provide clinicians with evidence-based management recommendations while outlining future research directions.
- 1 January 2026
- Published by Kare Publishing in Journal of Clinical Practice and Research
- Vol. 47 (6) , 565-572
Open Access1. Dupilumab-Induced Immune Drift Phenomena in Atopic Dermatitis: Novel Insights into Mechanisms and Therapeutic Strategies
Atopic dermatitis (AD) and psoriasis exhibit opposing T-cell polarization patterns and cytokine axes. Dupilumab, a monoclonal antibody targeting the interleukin-4/interleukin-13 (IL-4/IL-13) signaling pathway, has become a first-line biologic for moderate-to-severe AD. However, emerging clinical observations reveal that some patients with AD develop psoriasiform eruptions following biologic therapy, while certain patients with psoriasis may conversely develop eczematous lesions after corresponding biologic treatments. This paradoxical immune response has been termed the "immune drift phenomenon." This review synthesizes current evidence regarding the immunological mechanisms, clinical manifestations, histopathological characteristics, temporal patterns, and therapeutic strategies associated with this phenomenon, with particular emphasis on comprehensive management approaches, including topical therapies, systemic medication adjustments, biologic switching, and targeted small-molecule agents. In particular, it is important to acknowledge the potential limitations of small-molecule inhibitors, such as Janus kinase (JAK) inhibitors, or combination biologic therapies for managing immune drift, including the current lack of robust long-term safety and efficacy data in this specific context. We aim to provide clinicians with evidence-based management recommendations while outlining future research directions.
- 26 October 2025
- Published by Springer Nature in Targeted Oncology
- Vol. 20 (6) , 991-1001
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas
Background Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by plexiform neurofibromas (PNs), which are present in 20–60% of NF1 and may cause potentially life-threatening complications. Complete surgical resection of these PNs is generally not feasible, and regrowth after incomplete surgical resection has been observed. Luvometinib is a novel, oral, highly potent selective MEK1/2 inhibitor that has shown activity in adult NF1-related PN. Objective To evaluate the safety and preliminary efficacy of luvometinib in a phase 1 trial in pediatric patients with NF1-related PN. Patients and Methods This multicenter, single-arm, phase 1 study included pediatric patients (2–18 years old) with unresectable NF1-related PN. Patients received luvometinib orally once daily in 28-day cycles until progression or unacceptable toxicity, using a population pharmacokinetics model-informed approach to identify the starting dose of 4 mg/m2. Primary endpoints were dose-limiting toxicities (DLTs), maximum tolerated dose, and recommended phase 2 dose (RP2D). Tumor response was a secondary endpoint. Results In total, 19 patients were enrolled; 10 at 4 mg/m2 and 9 at 5 mg/m2. Median age was 10.0 years (range 5–17). No DLTs were reported. The maximum tolerated dose (MTD) was not reached; the RP2D was 5 mg/m2. The most common treatment-related adverse events (TRAEs) were paronychia (52.6%) and mouth ulceration (42.1%), with a single grade ≥ 3 TRAE reported for each: paronychia (5.3%), prolonged QT on electrocardiogram (5.3%), and ingrown nail (5.3%). There was one discontinuation owing to a treatment-related serious AE (SAE) of rhabdomyolysis, the only treatment-related SAE. Within the 5 mg/m2 group, six out of nine patients (66.7%) had a confirmed response; within the 4 mg/m2 group, none did. Among patients with tumor pain (numerical rating scale [NRS] ≥ 2) at baseline and at least one post-baseline measurement, 2/3 (66.7%) reported an improvement of ≥ 2 points in the 4 mg/m2 dose group and 3/3 (100.0%) in the 5 mg/m2 dose group. Conclusions Luvometinib had a manageable safety profile in pediatric patients with unresectable NF1-related PN. Encouraging preliminary efficacy was observed, particularly among patients receiving the RP2D of 5 mg/m2, supporting further investigation of luvometinib in this setting. Trial Registration ClinicalTrials.gov, NCT04954001 (first posted: 8 July 2021).
- 26 October 2025
- Published by Springer Nature in Targeted Oncology
- Vol. 20 (6) , 991-1001
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas
Background Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by plexiform neurofibromas (PNs), which are present in 20–60% of NF1 and may cause potentially life-threatening complications. Complete surgical resection of these PNs is generally not feasible, and regrowth after incomplete surgical resection has been observed. Luvometinib is a novel, oral, highly potent selective MEK1/2 inhibitor that has shown activity in adult NF1-related PN. Objective To evaluate the safety and preliminary efficacy of luvometinib in a phase 1 trial in pediatric patients with NF1-related PN. Patients and Methods This multicenter, single-arm, phase 1 study included pediatric patients (2–18 years old) with unresectable NF1-related PN. Patients received luvometinib orally once daily in 28-day cycles until progression or unacceptable toxicity, using a population pharmacokinetics model-informed approach to identify the starting dose of 4 mg/m2. Primary endpoints were dose-limiting toxicities (DLTs), maximum tolerated dose, and recommended phase 2 dose (RP2D). Tumor response was a secondary endpoint. Results In total, 19 patients were enrolled; 10 at 4 mg/m2 and 9 at 5 mg/m2. Median age was 10.0 years (range 5–17). No DLTs were reported. The maximum tolerated dose (MTD) was not reached; the RP2D was 5 mg/m2. The most common treatment-related adverse events (TRAEs) were paronychia (52.6%) and mouth ulceration (42.1%), with a single grade ≥ 3 TRAE reported for each: paronychia (5.3%), prolonged QT on electrocardiogram (5.3%), and ingrown nail (5.3%). There was one discontinuation owing to a treatment-related serious AE (SAE) of rhabdomyolysis, the only treatment-related SAE. Within the 5 mg/m2 group, six out of nine patients (66.7%) had a confirmed response; within the 4 mg/m2 group, none did. Among patients with tumor pain (numerical rating scale [NRS] ≥ 2) at baseline and at least one post-baseline measurement, 2/3 (66.7%) reported an improvement of ≥ 2 points in the 4 mg/m2 dose group and 3/3 (100.0%) in the 5 mg/m2 dose group. Conclusions Luvometinib had a manageable safety profile in pediatric patients with unresectable NF1-related PN. Encouraging preliminary efficacy was observed, particularly among patients receiving the RP2D of 5 mg/m2, supporting further investigation of luvometinib in this setting. Trial Registration ClinicalTrials.gov, NCT04954001 (first posted: 8 July 2021).
- 9 June 2025
- Published by Springer Nature in Immunologic Research
- Vol. 73 (1) , 1-6
Deucravacitinib as a monotherapy for concurrent management of psoriasis and chronic spontaneous urticaria
Patients with autoimmune diseases are susceptible to developing a second autoimmune disorder. Psoriasis, a common autoimmune disease, frequently occurs alongside other autoimmune conditions in some individuals. We report the case of a young female patient diagnosed with plaque psoriasis, initially treated with secukinumab, and achieved complete skin clearance at 12 weeks. However, she experienced a decline in the efficacy of secukinumab, with recurrence of symptoms and subsequent development of chronic spontaneous urticaria (CSU) and was switched to treatment with deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor. The use of deucravacitinib resulted in a favorable therapeutic outcome, effectively managing both psoriasis and CSU 12 weeks after treatment. This case highlights the potential of deucravacitinib as a novel monotherapy for patients with both psoriasis and CSU.
- 9 June 2025
- Published by Springer Nature in Immunologic Research
- Vol. 73 (1) , 1-6
Deucravacitinib as a monotherapy for concurrent management of psoriasis and chronic spontaneous urticaria
Patients with autoimmune diseases are susceptible to developing a second autoimmune disorder. Psoriasis, a common autoimmune disease, frequently occurs alongside other autoimmune conditions in some individuals. We report the case of a young female patient diagnosed with plaque psoriasis, initially treated with secukinumab, and achieved complete skin clearance at 12 weeks. However, she experienced a decline in the efficacy of secukinumab, with recurrence of symptoms and subsequent development of chronic spontaneous urticaria (CSU) and was switched to treatment with deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor. The use of deucravacitinib resulted in a favorable therapeutic outcome, effectively managing both psoriasis and CSU 12 weeks after treatment. This case highlights the potential of deucravacitinib as a novel monotherapy for patients with both psoriasis and CSU.
- Open Access
- 24 April 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1544312
Subacute cutaneous lupus erythematosus triggered by sintilimab: a case report
Immune checkpoint inhibitors (ICIs) have become a standard treatment for various cancers, but their use is often associated with immune-related adverse events (irAEs), including cutaneous irAEs (cirAEs). Here, we report a rare case of subacute cutaneous lupus erythematosus (SCLE) induced by sintilimab, a PD-1 inhibitor, in a 30-year-old woman undergoing neoadjuvant chemo-immunotherapy for gastric cancer. The patient presented with erythema, macules, papules, and vesicles, with positive ANA (108U/mL) and strongly positive anti-SSA/Ro. After discontinuation of sintilimab and treatment with corticosteroids, hydroxychloroquine, and intravenous immunoglobulin (IVIG), her symptoms improved. This case represents the first reported instance of drug-induced lupus caused by sintilimab and emphasizes the importance of distinguishing between paraneoplastic lupus and ICI-induced lupus.
- 24 April 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1544312
Open AccessSubacute cutaneous lupus erythematosus triggered by sintilimab: a case report
Immune checkpoint inhibitors (ICIs) have become a standard treatment for various cancers, but their use is often associated with immune-related adverse events (irAEs), including cutaneous irAEs (cirAEs). Here, we report a rare case of subacute cutaneous lupus erythematosus (SCLE) induced by sintilimab, a PD-1 inhibitor, in a 30-year-old woman undergoing neoadjuvant chemo-immunotherapy for gastric cancer. The patient presented with erythema, macules, papules, and vesicles, with positive ANA (108U/mL) and strongly positive anti-SSA/Ro. After discontinuation of sintilimab and treatment with corticosteroids, hydroxychloroquine, and intravenous immunoglobulin (IVIG), her symptoms improved. This case represents the first reported instance of drug-induced lupus caused by sintilimab and emphasizes the importance of distinguishing between paraneoplastic lupus and ICI-induced lupus.
- 18 April 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (4) , e0167922
Biological Evaluation of the Antibacterial Retinoid CD437 in Cutibacterium acnes Infection
Acne vulgaris is a complex skin disease involving infection by Cutibacterium acnes , inflammation, and hyperkeratinization. We evaluated the activity of the retinoid 6-[3-(adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) and 16 other retinoid analogs as potential anti- C. acnes compounds and found that CD437 displayed the highest antimicrobial activity with an MIC against C. acnes (ATCC 6919 and HM-513) of 1 μg/mL.
- 18 April 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (4) , e0167922
Biological Evaluation of the Antibacterial Retinoid CD437 in Cutibacterium acnes Infection
Acne vulgaris is a complex skin disease involving infection by Cutibacterium acnes , inflammation, and hyperkeratinization. We evaluated the activity of the retinoid 6-[3-(adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) and 16 other retinoid analogs as potential anti- C. acnes compounds and found that CD437 displayed the highest antimicrobial activity with an MIC against C. acnes (ATCC 6919 and HM-513) of 1 μg/mL.
- 28 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (7) , 1313-1317.e8
Variants in the Gene Encoding Filaggrin Cause Autosomal-Dominant Symmetrical Acral Keratoderma
- 28 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (7) , 1313-1317.e8
Variants in the Gene Encoding Filaggrin Cause Autosomal-Dominant Symmetrical Acral Keratoderma
- Open Access
- 16 December 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 10 (35) , 13064-13073
Successful surgical treatment of polybacterial gas gangrene confirmed by metagenomic next-generation sequencing detection: A case report
We report on a case of Vibrio vulnificus (V. vulnificus) detected by metagenomics next-generation sequencing (mNGS) in a 53-year-old male patient with polymicrobial gas gangrene and successful treatment by surgery. This report raises awareness among dermatologists that when a patient is clinically suspected of a special type of pathogenic infection, the mNGS method should be preferred to identify the patient’s pathogen infection as soon as possible and then take effective treatment in time to save patients’ lives. A 53-year-old male who worked in the aquatic market complained of redness and swelling of the lower limbs, blisters and ulcers with fever for 3 d. We used mNGS to test the pathogens in ulcer secretions. The results were returned in 24 h and indicated: V. vulnificus, Fusobacterium necrophorum, Staphylococcus haemolyticus, Staphylococcus aureus, Streptococcus dysgalactiae and Klebsiella aerogenes. This patient was diagnosed with V. vulnificus infection. The emergency operation was per formed immediately under combined lumbar and epidural anesthesia: Left leg expansion and exploration (August 10, 2021). After surgery, we continued to use piperacillin sodium tazobactam sodium 4.5 g every 8 h and levofloxacin 0.5 g for anti-infection treatment. The patient underwent further surgery under lumbar anesthesia on August 17, 2021 and August 31, 2021: Left leg deactivation and skin grafting, negative pressure closed drainage and right thigh skin removal. After treatment, the transplanted flap survived. We could confirm the diagnosis of Vibrio vulnificus infection within 24 h through mNGS detection and then immediately performed emergency surgery.
- 16 December 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 10 (35) , 13064-13073
Open AccessSuccessful surgical treatment of polybacterial gas gangrene confirmed by metagenomic next-generation sequencing detection: A case report
We report on a case of Vibrio vulnificus (V. vulnificus) detected by metagenomics next-generation sequencing (mNGS) in a 53-year-old male patient with polymicrobial gas gangrene and successful treatment by surgery. This report raises awareness among dermatologists that when a patient is clinically suspected of a special type of pathogenic infection, the mNGS method should be preferred to identify the patient’s pathogen infection as soon as possible and then take effective treatment in time to save patients’ lives. A 53-year-old male who worked in the aquatic market complained of redness and swelling of the lower limbs, blisters and ulcers with fever for 3 d. We used mNGS to test the pathogens in ulcer secretions. The results were returned in 24 h and indicated: V. vulnificus, Fusobacterium necrophorum, Staphylococcus haemolyticus, Staphylococcus aureus, Streptococcus dysgalactiae and Klebsiella aerogenes. This patient was diagnosed with V. vulnificus infection. The emergency operation was per formed immediately under combined lumbar and epidural anesthesia: Left leg expansion and exploration (August 10, 2021). After surgery, we continued to use piperacillin sodium tazobactam sodium 4.5 g every 8 h and levofloxacin 0.5 g for anti-infection treatment. The patient underwent further surgery under lumbar anesthesia on August 17, 2021 and August 31, 2021: Left leg deactivation and skin grafting, negative pressure closed drainage and right thigh skin removal. After treatment, the transplanted flap survived. We could confirm the diagnosis of Vibrio vulnificus infection within 24 h through mNGS detection and then immediately performed emergency surgery.